Key Points
- Guardant Health insider John Saia sold 10,000 shares on May 27 at an average price of $125.08, totaling $1.25 million. After the transaction, he still held 35,950 shares, and the sale was made under a pre-arranged Rule 10b5-1 trading plan.
- The stock was trading higher, opening at $133.22 and up 4.5% on Friday, near its 52-week high of $133.71. Guardant Health now has a market cap of about $17.66 billion.
- Analysts remain mostly bullish on GH, with 19 Buy ratings, one Hold, and one Sell, and an average target price of $129.79. Recent price targets from firms like Canaccord, BTIG, and Leerink were raised as high as $180.
Guardant Health, Inc. (NASDAQ:GH - Get Free Report) insider John Saia sold 10,000 shares of Guardant Health stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $125.08, for a total value of $1,250,800.00. Following the sale, the insider directly owned 35,950 shares in the company, valued at approximately $4,496,626. This trade represents a 21.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Guardant Health Trading Up 4.5%
GH opened at $133.22 on Friday. The business's 50 day moving average is $94.23 and its 200-day moving average is $99.73. The stock has a market cap of $17.66 billion, a PE ratio of -39.30 and a beta of 1.48. Guardant Health, Inc. has a twelve month low of $38.03 and a twelve month high of $133.71.
Wall Street Analyst Weigh In
A number of research firms have recently weighed in on GH. Canaccord Genuity Group lifted their price target on Guardant Health from $125.00 to $135.00 and gave the company a "buy" rating in a report on Friday, February 20th. BTIG Research set a $160.00 price objective on shares of Guardant Health and gave the stock a "buy" rating in a report on Wednesday. Evercore set a $110.00 price objective on shares of Guardant Health in a report on Friday, February 20th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Guardant Health in a report on Tuesday, April 21st. Finally, Leerink Partners upped their price objective on shares of Guardant Health from $170.00 to $180.00 and gave the stock an "outperform" rating in a report on Friday, February 20th. Nineteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Guardant Health currently has an average rating of "Moderate Buy" and an average target price of $129.79.
View Our Latest Research Report on Guardant Health
Institutional Investors Weigh In On Guardant Health
Several hedge funds and other institutional investors have recently bought and sold shares of the business. V Square Quantitative Management LLC bought a new position in shares of Guardant Health in the fourth quarter valued at $27,000. Chesapeake Asset Management LLC bought a new position in shares of Guardant Health in the fourth quarter valued at $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Guardant Health during the 4th quarter worth about $31,000. Elyxium Wealth LLC acquired a new stake in Guardant Health during the 4th quarter worth about $35,000. Finally, Parallel Advisors LLC raised its holdings in Guardant Health by 164.7% during the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company's stock worth $36,000 after buying an additional 219 shares during the period. 92.60% of the stock is currently owned by institutional investors.
About Guardant Health
(
Get Free Report)
Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.
The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
